{"id":"W4407150890","doi":"10.1038/s41591-024-03485-7","title":"Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial","year":2025,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":110,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; BC Cancer Agency; Institute of Cancer Research; University of Alberta; University of Calgary","funders":"National Cancer Institute","keywords":"Medicine; Daratumumab; Multiple myeloma; Lenalidomide; Internal medicine; Hazard ratio; Bortezomib; Clinical endpoint; Transplantation; Surgery; Oncology; Confidence interval; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001969202,0.0007237052,0.001418229,0.0001928914,0.0003714216,0.0008893179,0.0005040409,0.0007588287,0.003405643],"category_scores_gemma":[0.001275357,0.0002590372,0.001343492,0.0002360761,0.0005524655,0.0006364529,0.0003757175,0.002164666,0.000376593],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007422542,"about_ca_system_score_gemma":0.001097087,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008187906,"about_ca_topic_score_gemma":0.002230467,"domain_scores_codex":[0.9994548,0.0003551768,0.0000221882,0.00006872512,0.00003722287,0.00006196653],"domain_scores_gemma":[0.9992472,0.0001832464,0.0001967258,0.00004247671,0.00003812042,0.0002923525],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9674969,0.003529271,0.001972194,0.0003094782,0.0008684502,0.00005963644,0.0000433859,0.0006701126,0.00187175,0.0002971381,0.002489194,0.02039249],"study_design_scores_gemma":[0.9330159,0.05823807,0.00407856,0.00005869783,0.0007734102,0.0001158692,0.00003167634,0.001079475,0.0004710145,0.000407889,0.001714938,0.0000144859],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9884945,0.005880177,0.0004296064,0.001189445,0.0004759356,0.001236694,0.0006681075,0.00006197105,0.001563728],"genre_scores_gemma":[0.9907821,0.002366816,0.001024214,0.001458179,0.0003540585,0.001298633,0.001007503,0.0000182443,0.001690318],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003405643,"threshold_uncertainty_score":0.01139295,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03095167995952319,"score_gpt":0.3699476036177096,"score_spread":0.3389959236581864,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}